MGO One Seven’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$286K Sell
7,789
-1,210
-13% -$57.3K 0.01% 1154
2025
Q4
$458K Sell
8,999
-16,037
-64% -$820K 0.01% 911
2025
Q3
$1.39M Sell
25,036
-25,118
-50% -$1.47M 0.03% 499
2025
Q2
$3.46M Buy
50,154
+32,432
+183% +$2.21M 0.11% 204
2025
Q1
$1.23M Sell
17,722
-2,344
-12% -$194K 0.05% 387
2024
Q4
$1.73M Buy
20,066
+2,413
+14% +$261K 0.07% 306
2024
Q3
$2.1M Sell
17,653
-2,146
-11% -$286K 0.09% 241
2024
Q2
$2.83M Buy
19,799
+3,629
+22% +$481K 0.13% 175
2024
Q1
$2.08M Sell
16,170
-1,460
-8% -$174K 0.11% 212
2023
Q4
$1.82M Buy
17,630
+600
+4% +$59.3K 0.1% 217
2023
Q3
$1.55M Buy
17,030
+1,436
+9% +$126K 0.12% 194
2023
Q2
$1.26M Sell
15,594
-912
-6% -$74.5K 0.12% 209
2023
Q1
$1.31M Buy
16,506
+734
+5% +$52K 0.08% 254
2022
Q4
$1.07M Buy
15,772
+150
+1% +$8.79K 0.11% 215
2022
Q3
$778 Sell
15,622
-1,646
-10% -$88.2K 0.03% 290
2022
Q2
$962K Sell
17,268
-9,156
-35% -$508K 0.13% 179
2022
Q1
$1.13M Sell
26,424
-376
-1% -$19.3K 0.12% 193
2021
Q4
$1.16M Buy
26,800
+2,064
+8% +$112K 0.12% 203
2021
Q3
$1.03M Buy
24,736
+2,216
+10% +$107K 0.13% 194
2021
Q2
$690K Buy
22,520
+332
+1% +$12.9K 0.1% 263
2021
Q1
$544K Sell
22,188
-1,338
-6% -$47.7K 0.09% 278
2020
Q4
$611K Buy
23,526
+6
+0% +$207 0.13% 217
2020
Q3
$607K Sell
23,520
-370
-2% -$12.3K 0.14% 184
2020
Q2
$585K Buy
23,890
+6,580
+38% +$210K 0.15% 187
2020
Q1
$521K Buy
17,310
+1,062
+7% +$31.6K 0.18% 161
2019
Q4
$470K Buy
+16,248
New +$450K 0.12% 229
2019
Q1
Sell
-2,004
Closed -$46K 1227
2018
Q4
$46K Buy
+2,004
New +$44.5K 0.02% 656
2018
Q1
$56K Sell
2,288
-1,400
-38% -$36.8K 0.03% 585
2017
Q4
$99K Buy
+3,688
New +$93.8K 0.05% 440

Other funds holding NVO

MGO One Seven's NVO Position: Q1 2026 in Review

MGO One Seven reduced its Novo Nordisk (NVO) stake by 13% in Q1 2026, selling an estimated $57.3K and leaving 7,789 shares worth $286K. The position accounts for 0.01% of the portfolio, ranked #1154.

MGO One Seven first reported a position in NVO in Q4 2017 and has held it in 29 quarters since. The position peaked at $3.46M in Q2 2025. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • MGO One Seven held 7,789 shares of Novo Nordisk worth $286K as of Q1 2026.
  • MGO One Seven sold 1,210 Novo Nordisk shares in Q1 2026, an estimated $57.3K.
  • Novo Nordisk made up 0.01% of MGO One Seven's portfolio in Q1 2026, its #1154 holding.
  • MGO One Seven first reported a position in Novo Nordisk in Q4 2017 and has held it in 29 quarters since.
  • MGO One Seven's Novo Nordisk position peaked at $3.46M in Q2 2025.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on MGO One Seven's 13F filing for Q1 2026, filed 14 May 2026.